Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory updates and sector-specific developments have contributed to the much ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Novo Nordisk A/S is a biopharma company that has specialized in the diabetes market for a long time. This is an attractive market to be in, as there are significant unmet medical needs since the ...

As a 100-year old company focused on treating diabetes since day one, Novo Nordisk initially enjoyed a first-mover advantage—but that edge has faded. Novo Nordisk’s semaglutide drug is in a ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight ... Shares had skyrocketed after the introduction of Wegovy and diabetes medicine Ozempic, which are both based on the ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.